Introduction
Eluxadoline is a prescription medication used to treat irritable bowel syndrome with diarrhea (IBS-D) in adults. It is a mu-opioid receptor agonist and delta-opioid receptor antagonist that helps to reduce bowel movements and improve abdominal symptoms associated with IBS-D.
Uses
Eluxadoline is specifically used for:
- Irritable Bowel Syndrome with Diarrhea (IBS-D): It helps manage symptoms such as abdominal pain, cramping, and diarrhea in adults with IBS-D.
| Brand Name | Eluxadoline |
|---|---|
| Type | |
| Weight | |
| Generic | Eluxadoline |
| Manufacturer | |
| Available in | English বাংলা |
Mechanism of Action
Eluxadoline works by acting on opioid receptors in the gut. It binds to mu-opioid receptors as an agonist, which helps reduce bowel movements and control diarrhea. Simultaneously, it acts as an antagonist at delta-opioid receptors, which helps to alleviate abdominal pain and discomfort. This dual action helps improve overall gastrointestinal function and symptoms.
How Long Does It Take to Work?
Eluxadoline typically begins to show its effects within a few days to a week of starting treatment. Most patients experience noticeable improvement in IBS-D symptoms within 1 to 2 weeks. Full therapeutic effects may take up to 4 to 6 weeks.
Absorption
Eluxadoline is rapidly absorbed after oral administration. Peak plasma concentrations are usually reached within 2 to 4 hours. The drug has a high bioavailability, meaning that a significant proportion of the drug reaches systemic circulation after ingestion.
Route of Elimination
Eluxadoline is primarily metabolized by the liver. It undergoes extensive first-pass metabolism, which means that a significant portion of the drug is metabolized before it reaches systemic circulation. The drug and its metabolites are mainly excreted in the feces, with a minor amount eliminated in the urine.
Dosage
The recommended dose is 75 mg tablet taken orally twice daily with food. Patients who develop severe constipation for more than 4 days have to discontinue the drug. If a dose is missed, patient should take the next dose at the regular time and avoid taking two doses at a time.Pediatric Use: Safety and effectiveness in pediatric patients have not been established.
Hepatic Impairment: It is contraindicated in patients with severe hepatic impairment.
The usual dosage of Eluxadoline for treating IBS-D is:
- Initial Dose: 100 mg taken orally twice daily.
- Maintenance Dose: If well-tolerated, the dose may be increased to 200 mg twice daily.
Dosage may be adjusted based on individual response and tolerance. Follow healthcare provider recommendations for specific dosing instructions.
Administration
Eluxadoline should be administered orally with or without food. It is important to take the medication exactly as prescribed by the healthcare provider. Tablets should be swallowed whole and not chewed or crushed.
Side Effects
Common side effects of Eluxadoline include:
- Nausea
- Constipation
- Abdominal pain
- Headache
- Dizziness
Less common but more serious side effects may include severe abdominal pain, pancreatitis, and liver enzyme abnormalities. Seek medical attention if severe side effects occur.
Toxicity
Toxicity from Eluxadoline is rare but can occur, particularly with overdose. Symptoms of toxicity may include severe nausea, vomiting, constipation, and abdominal pain. In case of overdose, seek immediate medical attention for appropriate management and treatment.
Precautions
Precautions for Eluxadoline use include:
- Monitor for signs of pancreatitis, particularly in patients with a history of pancreatic disorders.
- Be cautious in patients with liver impairment, as Eluxadoline is metabolized by the liver.
- Assess for potential interactions with other medications that may affect gastrointestinal motility.
Interaction
Eluxadoline may interact with other medications, including:
- Strong CYP3A4 inhibitors (e.g., ketoconazole), which can increase Eluxadoline levels and the risk of side effects.
- Drugs that affect gastrointestinal motility, which may impact Eluxadoline 's effectiveness.
Disease Interaction
Eluxadoline should be used with caution in patients with:
- Pancreatic disorders: Due to the risk of pancreatitis.
- Liver impairment: As the drug is metabolized by the liver and may require dose adjustment.
Drug Interaction
Drug interactions may include:
- Other medications that affect CYP3A4 enzyme activity.
- Concomitant use with opioids or medications that affect opioid receptors.
Food Interactions
There are no significant food interactions with Eluxadoline . It can be taken with or without food. However, patients should follow specific dietary recommendations provided by their healthcare provider to avoid exacerbating IBS-D symptoms.
Pregnancy Use
Eluxadoline is categorized as a Category C drug for pregnancy, meaning that risk to the fetus cannot be ruled out. It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Consult with a healthcare provider before using Eluxadoline during pregnancy.
Lactation Use
The safety of Eluxadoline during lactation is not well established. It is not known if Eluxadoline passes into breast milk. Use caution if breastfeeding, and discuss with a healthcare provider whether to continue the medication or alternative treatments.
Acute Overdose
In the event of acute overdose, symptoms may include severe nausea, constipation, and abdominal pain. Immediate medical attention is required. Treatment typically involves supportive care and symptomatic management.
Contraindication
Eluxadoline is contraindicated in individuals with:
- Known hypersensitivity to Eluxadoline or any of its components.
- Severe liver impairment or disease.
- History of pancreatitis.
- Patients who do not have a gallbladder, as the risk of pancreatitis is higher.
Use Direction
Take Eluxadoline exactly as prescribed by the healthcare provider. Do not alter the dose or frequency without medical advice. Consistency in taking the medication is key to managing symptoms effectively.
Storage Conditions
Store Eluxadoline at room temperature, away from moisture and direct sunlight. Keep the medication in its original container, tightly closed, and out of reach of children.
Volume of Distribution
The volume of distribution for Eluxadoline is not widely specified. It is distributed throughout the body after oral administration, with a focus on the gastrointestinal tract where it exerts its primary effects.
Half Life
The half-life of Eluxadoline is approximately 5 to 6 hours. This relatively short half-life influences the dosing schedule, typically requiring administration twice daily.
Clearance
Eluxadoline is primarily cleared through the liver, with a minor amount excreted in the urine. The clearance rate can be affected by liver function and potential drug interactions. Monitoring and dose adjustments may be required for individuals with liver impairment.
See in details version Eluxadoline also Eluxadoline in bangla
